Study of Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Medicinal Product MediReg®

Launched by LOMONOSOV MOSCOW STATE UNIVERSITY MEDICAL RESEARCH AND EDUCATIONAL CENTER · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called MediReg® to help men with severe infertility issues, specifically those who have conditions like azoospermia (no sperm present), teratospermia (abnormal sperm), or oligospermia (low sperm count). The goal of the trial is to see if this treatment can improve sperm quality, which may boost the chances of successful conception, especially with assisted reproductive technologies. The trial is being conducted at Lomonosov Moscow State University and has been approved by the Ministry of Health of the Russian Federation.

To participate, men aged 21 to 60 years must have specific severe sperm issues that have not improved over at least 12 months. Participants will receive a single injection of the study drug under the skin of both testicles and will stay in the hospital for one week for observation. After that, there will be outpatient visits for follow-up over the next three months. The entire process, including screening and follow-ups, will last up to 119 days. It’s important for participants and their partners to use reliable contraceptive methods during the study and for a month afterward. If you or someone you know is facing challenges with male infertility, this trial could offer a potential new avenue for treatment.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Male patients aged 21-60 years at the time of inclusion in the study. 2. Persistent severe disorders of spermatogenesis, manifested as severe oligoasthenoteratozoospermia (OAT)\*, non-obstructive azoospermia, high sperm DNA fragmentation (30% or more), including those caused by secretory infertility according to dynamic control of spermogram (at least 12 months from the moment of inclusion in the study).
• • "Persistent severe OAT" should be considered as disorders when sperm concentration \<5 million/mL, progressively motile sperm \<13% and/or total number of progressively motile sperm in the ejaculate (PMPM) \<5 million, with the proportion of normal sperm \<1% according to the dynamic control of spermogram (at least 12 months from the moment of inclusion in the study).
• • 3. inability to conceive against the background of "severe forms" of male infertility, not amenable to treatment, including assisted reproductive technologies, within 12 months from the moment of diagnosis or refusal to use assisted reproductive technologies.
• • 4. Voluntarily signed Informed consent by the patient to participate in the clinical trial.
• • 5. Willingness of patients and their sexual partners to use reliable contraceptive methods (combination of at least 2 methods, including 1 barrier method, e.g., use of spermicide and condom) from the time of signing the informed consent until at least 1 month after completion of study participation.
• • 6. Patient willingness to follow all the requirements of the Protocol.
• Exclusion Criteria:
• • 1. Age younger than 21 and older than 60 years at the time of inclusion in the study.
• • 2. developmental anomalies of the genitourinary system (according to bladder and kidney ultrasound).
• • 3. surgical interventions on genitourinary organs in the history, except for surgical interventions associated with assisted reproductive technologies. 4.
• • 4. Systemic diseases requiring administration of corticosteroids, cytostatics, radiation therapy.
• • 5. Inflammatory diseases of the urinary and/or reproductive system. 6. Infectious diseases (including STDs) of the urinary and/or reproductive system.
• • 7. Hereditary factors of infertility: (Klinefelter syndrome (all variants), autosomal abnormalities (all variants), carrying the cystic fibrosis gene (all variants), presence of Y-chromosome microdeletions (all AZF variants), autosomal defects with severe phenotypic abnormalities and infertility (Prader-Willi, Bardet-Biedl, Noonan syndromes, myotonic dystrophy, dominant polycystic kidney disease, 5-alpha-reductase enzyme deficiency, etc.). д.).
• • 8. Obstructive azoospermia by history or established by screening examination. 9. Positive test for HIV, hepatitis B and C, syphilis. 10. Severe liver failure or active liver disease (transaminase activity exceeding 5 times the upper limit of the local laboratory norm).
• • 11. Renal dysfunction with serum creatinine levels exceeding 120 µmol/L. 12. Cardiovascular diseases in the history within 6 months before inclusion in the study, such as myocardial infarction, angina pectoris, severe ventricular arrhythmia, heart failure (NYHA class II-IV).
• • 13. Neurologic (Parkinson's disease) and/or psychiatric illnesses with a history or established by screening examination.
• • 14. Cancer with a history of cancer or as determined by screening examination (as determined by OBP and renal ultrasound, bladder ultrasound, prostate TRUS).
• • 15. Hypersensitivity to any of the components of the study drug in the history. 16. Mental illness, severe cognitive impairment, need to take tranquilizers, neuroleptics and/or antidepressants during this study.
• • 17. Severe somatic illnesses that, in the opinion of the investigator, may affect the patient's safety and ability to comply with the Protocol.
• • 18. A history of drug dependence. 19. Positive urinalysis for psychotropic and narcotic drugs, psychoactive medications.
• • 20. Intake of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to 1⁄2 liter of beer, 200 ml of wine, or 50 ml of alcohol) or a history of alcoholism.
• • 21. Detection of alcohol vapor in breath 22. Participation in another clinical trial currently or in the previous 30 days prior to the screening visit.
• • 23. Patient's inability to understand or comply with study procedures or patient's refusal to cooperate with a particular investigator